Crossmark

Artesunate shows potent anti-tumor activity in B-cell lymphoma

Crossref DOI link: https://doi.org/10.1186/s13045-018-0561-0

Published Online: 2018-02-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Våtsveen, Thea Kristin https://orcid.org/0000-0002-4158-0617
Myhre, Marit Renée

Steen, Chloé Beate

Wälchli, Sébastien

Lingjærde, Ole Christian

Bai, Baoyan

Dillard, Pierre

Theodossiou, Theodossis A.

Holien, Toril

Sundan, Anders

Inderberg, Else Marit

Smeland, Erlend B.

Myklebust, June Helen

Oksvold, Morten P.
Funding

Funding for this research was provided by:

Helse Sør-Øst RHF

Kreftforeningen
More Information

Article History

Received: 14 November 2017

Accepted: 29 January 2018

First Online: 20 February 2018

Ethics approval

: The care and handling of animals for the present study were in conformity with the Norwegian Food Safety Authority in compliance with the European Convention of the Protection of Vertebrates Used for Scientific Purposes (Project ID 7729).

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.